In-licensing transforms Mosaic from a research and platform company to a clinical-stage oncology business
Mosaic will develop proprietary, targeted combination products, supported by proprietary biomarkers, to realise the full potential of the assets
As part of the agreement Astex has taken an equity stake in Mosaic
Cambridge, UK, 24 April 2025 – Mosaic Therapeutics, Ltd (‘Mosaic’, or ‘the Company’) a targeted oncology therapeutics company dedicated to resolving cancer’s complexity with new combination therapies for patients, today announces the in-licensing of two clinical-stage oncology…
Amsbio has launched a new range of Deubiquitinating (DUB) enzyme assay kits supplied in a convenient and easy-to-use 96-well assay format. With minimal setup required and no need for substrate preparation, these ready-to-use kits accelerate routine DUB activity assays without compromising data quality.
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. The DUB enzyme family contains around 100 proteins that remove ubiquitin from a variety of substrates. Widely…
Reflects the potential of EvoLiver test to improve early liver cancer detection among high-risk patients
EvoLiver leverages Mursla Bio’s platform based on organ-specific extracellular vesicles circulating in blood
Breakthrough status provides expedited review and closer collaboration with the FDA, ultimately enabling broader market reach and commercial adoption
Cambridge, UK, and Boston MA, USA, 23 April 2025: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of Dynamic Biopsy technology,…
• Focus on high value R&D underpinned by Arestat™ technology and Company expertise positions Arecor for significant future growth and success• Significant advancements in diabetes portfolio with positive progress towards strategic partnership for AT278• Potential to unlock significant value through innovation in the oral delivery of peptides• Growing revenue stream from AT220 global royalties• Expansion of partnership portfolio and licensing of Arestat™-enhanced products•…
Armed with a potent membrane protein production arsenal, Creative Biolabs stands by to lend a helping hand to researchers across the world so as to avoid the "doom loop" that has haunted membrane protein research for decades.Step aside AI and CRISPR—there's a new darling in biotech—membrane proteins, the cell gatekeepers behind 60% of all drug targets, are getting their time in the spotlight as breakthroughs in structural biology and drug design enter the mix and stimulate a frenzy of innovations. Creative Biolabs provides satisfactory membrane protein products and relatively flexible options…
Leading global drug development consultancy Boyds has strengthened its team with the appointment of senior regulatory affairs professional Kelsey Lenoch.
Kelsey joins Boyds as Associate Director, Regulatory Affairs in the US, bringing with her 15 years of experience in clinical research and drug development.
Previously, Kelsey was Senior Manager, Regulatory Affairs at Usona Institute, a non-profit medical research organization in Madison, Wisconsin, USA, working across both regulatory strategy and CMC development, supporting the clinical development of multiple psychedelic drugs. Prior to…
Membrane proteins synthesized and purified within 48 hours.
Active membrane transporter, MsbA and integral membrane protein, ZMPSTE24 synthesized
Cambridge, UK, and Boston MA, USA, 14 April 2025: Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, today announced the addition of a new membrane protein workflow to its system. This expanded capability enables the expression, purification and stabilization of challenging membrane proteins, which are often key targets in therapeutic development. Using cell-free…
Creative Biolabs stands out in the race as brain diseases fuel a surge in demand for NHP biospecimens—cerebrospinal fluid (CSF)—functioning as the gold standard for validating next-gen brain therapies.A landmark study about gene therapy recently reported in Nature Biotechnology indicating 27% cognitive improvement in Alzheimer's mice using circular RNA has set labs scrambling for high-quality NHP samples that are firmly determined as the gold standard for bridging preclinical breakthroughs to human trials."Monkey CSF is more than just liquid, but a roadmap to the brain," says a neurology…
Working with leading research institutions, Amsbio has established itself as a premier supplier of high quality Heparan Sulfate (HS) monoclonal antibodies driving breakthroughs in Glycobiology research.
Heparan Sulfate (HS) is widely distributed on cell surfaces and basement membranes in mammals. It participates in important biological processes due to displaying specific interactions with many biologically active proteins. However, due to its non-immunogenic nature, developing effective antibodies against HS has long been a challenge.
Amsbio has overcome these…
Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
One Nucleus, the Cambridge based not-for-profit membership organisation for life science businesses, is delighted to announce the appointment of Melanie Leveridge, Vice President, Assays, Profiling & Cell Sciences, AstraZeneca, as a Non-Executive Director.
Melanie is an established preclinical drug discovery leader with a track record of developing and inspiring diverse, high performing teams, to deliver innovative science and technology. Melanie…